These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 26040387)

  • 1. [Active interventions in hypercholesteroloemia patients with high cardiovascular risk in primary care; estudio ESPROCOL].
    Tárraga López PJ; García-Norro Herreros FJ; Tárraga Marcos L; Solera Albero J; González López E; Ruiz García A; Pallarés Carratalá V; Castro Navarro JL; Alins Presas J; Panisello Royo JM
    Nutr Hosp; 2015 Jun; 31(6):2727-34. PubMed ID: 26040387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Active interventions in hypercholesteroloemia patients with high cardivascular risk in primary care].
    Tárraga López PJ; Garcia-Norro Herreros FJ; Tárraga Marcos L; Solera Albero J; González López E; Ruiz García A; Pallarés Carratalá V; Castro Navarro JL; Alins Presas J; Panisello Royo JM
    Nutr Hosp; 2015 May; 31(5):2261-8. PubMed ID: 25929402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cholesterolemia control in Spain, 2000. A tool for cardiovascular disease prevention. Ministry of Health and Consumption, Spanish Society of Cardiology and Spanish Society of Arteriosclerosis].
    Rev Esp Salud Publica; 2000; 74(3):215-53. PubMed ID: 10918811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Screening for hyperlipidemia in cardiovascular high-risk patients in austrian diabetes ambulances].
    Brath H; Wascher TC; Kästenbauer T; Toplak H
    MMW Fortschr Med; 2012 Jun; 154 Suppl 2():41-7. PubMed ID: 23424754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease].
    Pérez A; González Blanco C; Hernández-Presa MÁ; Chaves J
    Endocrinol Nutr; 2011; 58(6):283-90. PubMed ID: 21641286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Factors predictive of cardiovascular disease in patients with type-2 diabetes and hypercholesterolemia. ESODIAH study].
    Pintó X; Corbella E; Figueras R; Biarnés J; Ricart W; Morales C; Falkon L; Masana L;
    Rev Esp Cardiol; 2007 Mar; 60(3):251-8. PubMed ID: 17394870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of Secondary Data to Determine the Prevalence of Cardiovascular High Risk Patients with Hypercholesterolemia and Refractory Course of Treatment].
    Dippel FW; Parhofer KG; Müller-Bohn T; Gebhardt S; Kostev K
    Dtsch Med Wochenschr; 2017 Mar; 142(6):e34-e41. PubMed ID: 28329898
    [No Abstract]   [Full Text] [Related]  

  • 11. Predictors of uncontrolled hyperlipidaemia in high-risk ambulatory patients in primary care.
    Hildemann S; Karmann B; Pittrow D; Barho C; Darius H; Bode C
    Curr Med Res Opin; 2008 Jun; 24(6):1659-68. PubMed ID: 18457604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease.
    Virani SS; Woodard LD; Chitwood SS; Landrum CR; Urech TH; Wang D; Murawsky J; Ballantyne CM; Petersen LA
    Am Heart J; 2011 Oct; 162(4):725-732.e1. PubMed ID: 21982666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cholesterolemia control in Spain, 2000: a tool for cardiovascular disease prevention].
    Plaza Pérez I; Villar Alvarez F; Mata López P; Pérez Jiménez F; Maiquez Galán A; Casasnovas Lenguas JA; Banegas Banegas JR; Tomás Abadal L; Rodríguez Artalejo F; Gil López E
    Rev Clin Esp; 2000 Sep; 200(9):494-515. PubMed ID: 11111397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
    Hobbs T; Caso R; McMahon D; Nymark M
    Altern Ther Health Med; 2014; 20(5):18-23. PubMed ID: 25141367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The SaM (Screening and Monitoring) approach to cardiovascular risk-reduction in primary care--cyclic monitoring and individual treatment of patients at cardiovascular risk using the electronic medical record.
    Rabinowitz I; Tamir A
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):56-62. PubMed ID: 15703507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH).
    McPherson R; Angus C; Murray P; Genest J;
    Am Heart J; 2001 Jun; 141(6):949-56. PubMed ID: 11376309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study.
    Tajima N; Kurata H; Nakaya N; Mizuno K; Ohashi Y; Kushiro T; Teramoto T; Uchiyama S; Nakamura H;
    Atherosclerosis; 2008 Aug; 199(2):455-62. PubMed ID: 18635188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.